AB1020 MUSCULOSKELETAL INVOLVEMENT IN INFLAMMATORY BOWEL DISEASE PATIENTS: A MONOCENTRIC EXPERIENCE

Background Musculoskeletal (MSK) symptoms, varying from arthralgia to arthritis are frequently reported by patients (pts) with inflammatory bowel diseases (IBD). A peripheral or axial joint involvement has been a similar range 5 30% and definite spondyloarthritis (SpA) diagnosis is present in up 46% of IBD [1-8]. To date, more comprehensive disease control requested the optimization treatment (choosing mono combination therapy strategy) improve both gastrointestinal musculoskeletal mandatory. Objectives evaluate rate MSK centric cohort pts consequent need optimize their therapeutical schemes. Methods gastroenterologist working out-patient clinic had selected who should be referred rheumatologic visit, on basis results questionnaire aimed at highlighting presence clinical features suggestive SpA. From January 1 st 2017 December 31 2022 have evaluated rheumatologist expert In case doubts about diagnosis, further examinations were requested. The SpA was made following ASAS criteria 2011. Results total 288 sent (140 CD, 127 UC, 21 not defined IBD). One hundred sixty-eight received only one rheumatological visit while, two twice times. make 37 MRI (30 for sacroiliac joints), 30 ultrasound assessment (mostly hands, wrists feet), 19 X-rays 23 blood tests Most (196/288, 68%) classified as SpA; 50/288 (17.4%) 24/288 (8.3%) SpA, 18/288 (6.3%) there an isolated entheseal involvement. recommended 138 (47.9%). particular, DMARD added 59 bDMARD prescribed 6 indications; moreover, 73 cases, choice between different approaches suggested gastroenterologist, order activity course. Conclusion Our confirm already published prevalence patients. relevant number pts, after evaluation, half modification rheumatologist, aiming improving context These data importance close collaboration gastroenterologists rheumatologists, thus quality care [9]. References [1]Bandyopadhyay D et al. Indian J Gastroenterol. 2015 [2]Kamo K Mod Rheumatol. [3]Leclerc-Jacob S Aliment Pharmacol Ther. 2014 [4]Shivashankar R 2013 [5]Stolwijk C Can [6]Beslek Rheumatol Int. 2009 [7]Palm O 2002 [8]Salvarani Scand 2001 [9]Olivieri I Autoimmun Rev. Acknowledgements: NIL. Disclosure Interests None Declared.